Emerging Companies Fund

Monthly Update: June 2026

Dear Fellow Investors,

Our Emerging Companies Fund was up +1.9%* in June vs -4.1% for the Emerging Companies Accumulation Index (XECAI) and +3.9% for the Small Industrials Accumulation Index (XSIAI). Since inception, the Fund has generated +5.5%* p.a. and a total return of +65.6%* (or +128.0%* if distributions have not been reinvested) vs +150.0% for the XECAI and +62.1% for the XSIAI.

After enduring a torrid few months, it was pleasing to see some buying support resume for a few of our key stocks. The factors driving this were a combination of tax loss selling gradually concluding, a more stable macro backdrop and some stock-specific news flow. We remain of the view that the macro backdrop will continue to trend in our favour which, when combined with some significant stock-specific catalysts and heavily oversold positions, should create the environment for very strong portfolio performance over the next six to 12 months. To that end, we note that July has started positively for the Fund.

Performance summary*

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Total	3M	12M
2017		-3.2%	+2.6%	-0.6%	-1.0%	+7.6%	+6.4%	+2.7%	+4.0%	+13.2%	+9.5%	+8.1%	+60.1%		
2018	-1.6%	+4.2%	+1.6%	+1.1%	+4.1%	+1.6%	-3.1%	+0.7%	-0.8%	-3.2%	-4.8%	-5.2%	-5.9%		
2019	+6.0%	+4.8%	+3.1%	+4.7%	+10.8%	+0.6%	+17.6%	+1.4%	+6.1%	+4.6%	-0.8%	-1.3%	+73.2%		
2020	-0.6%	-11.7%	-28.4%	+23.3%	+18.4%	+14.1%	+16.0%	+20.7%	+3.1%	+1.0%	+2.3%	+4.0%	+62.3%		
2021	+1.9%	+2.1%	-0.1%	+5.0%	-4.4%	+5.5%	-8.0%	+4.3%	-5.5%	+1.0%	-4.5%	-9.6%	-13.0%		
2022	-7.9%	-9.6%	-3.0%	-5.8%	-17.6%	-15.5%	+10.1%	-0.3%	-6.1%	+2.0%	-3.8%	-6.7%	-49.9%		
2023	-0.2%	-8.1%	-6.1%	+6.1%	-5.4%	-7.8%	+21.2%	-3.7%	-5.6%	-1.8%	+3.9%	+2.6%	-8.1%		
2024	-0.9%	-4.8%	+1.1%	-5.6%	-5.4%	+8.1%	+15.9%	-3.1%	+12.0%	+4.0%	+18.2%	+9.0%	+55.1%		
2025	+2.2%	-3.7%	-10.8%	+8.7%	-1.3%	-4.2%	-1.4%	+6.3%	-0.4%	+0.4%	-3.8%	+1.1%	-8.1%		
2026	+2.0%	-6.5%	-10.7%	-3.7%	-14.6%	+1.9%							-28.7%	-16.2%	-27.3%

Returns are based on the Main Series only, net of all base fees, performance fees and expenses of the Fund



*Past performance is no guarantee of future performance

Performance commentary

The key positive contributors during June were Biome Australia (BIO, +14%), Airtasker (ART, +7%) and Imricor (IMR, +5%). The key negative contributors were Murray Cod Australia (MCA, -12%), Terragen (TGH, -20%) and IDT Australia (IDT, -11%).

BIO signed a commercial manufacturing agreement with Specialty Probiotics Australia (SPA) to bring production of its *Activated Probiotics* range onshore. Importantly, and consistent with the Company's capital-light strategy, the agreement does not require BIO to make any upfront capital investment. BIO's already strong gross margin of ~61% is now expected to progressively increase to >65% over the next 18 months, commencing from the first commercial batch in September 2026. BIO also expects to generate a meaningful working capital benefit through lower inventory days, faster stock turn and the elimination of extended international sea freight. Furthermore, Australian-made production adds a point of difference across global markets. However, BIO will retain its European supply partnerships to service EU markets, ensuring it has supply chain diversification. While this development is consistent with BIO's 'Vision 27' strategy, execution of the agreement and confirmation of the expected working capital benefit and margin uplift was welcome news, especially for a stock that has been under so much selling pressure in recent months

IMR announced that it has submitted the third Premarket Approval (PMA) module for U.S. Food and Drug Administration (FDA) review. The third module covers the design, execution, and results of all non-clinical tests (e.g. product performance, sterile shelf life, software testing, magnetic resonance safety) associated with the Vision-MR Ablation Catheter 2.0, RF-5000 Ablation Generator, and RF-5000 Irrigation Tubing Set. IMR continues to execute a modular review process with the FDA, whereby modules covering various aspects of the Company's products are submitted and reviewed serially, with the goal of achieving a more streamlined review process. Concurrently, the team are pursuing multiple FDA clearances for their portfolio devices which follow the 510(k) pathway. So far, three products have received 510(k) clearance: NorthStar, Vision-MR Diagnostic Catheter, and Vision-MR Diagnostic Catheter Cable, with IMR reiterating that it remains on track for FDA approval and clearance of its platform products in the U.S. this year. This remains a significant catalyst for the stock and should drive a further share price re-rating.

We note with interest that starting 1 July 2026, new seafood labelling rules in Australia will come into effect, which has potentially significant positive implications for MCA and its competitive position. Under the new information standards, hospitality businesses which sell seafood for immediate consumption (such as restaurants, cafes, pubs, clubs and takeaway outlets) will be required to label seafood dishes with country of origin information using the Australian (A), Imported (I) or Mixed (M) model. Given so much of the seafood consumed in Australia is imported from overseas (for example, we understand that ~70% of barramundi consumed in Australia is imported from SE Asia), we think this could have a material impact on consumer preferences and behaviours. As a uniquely local and sustainably-grown product, we believe that Aquna Murray Cod is very well positioned to benefit from these changes, both in terms of increasing demand and preserving (if not, expanding) its price premium relative to other comparable fish that are often imported. Furthermore, given its rapidly expanding supply of fish available for sale, these changes are arguably being implemented at an optimal time for the Company.

Portfolio characteristics

We currently have ~97% of our capital invested in 10 stocks.



Please get in touch should you have any queries regarding the above. Thanks again for your interest and support and I look forward to providing another update in early August on our performance during July.

Kind regards,

Jonathan Collett
Principal
Saville Capital

+61 3 9769 1789
jcollett@savillecapital.com

Important Information